S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:EYES

Second Sight Medical Products Stock Forecast, Price & News

$5.79
+4.36 (+304.90 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.07
Now: $5.79
$9.89
50-Day Range
$1.43
MA: $2.12
$2.63
52-Week Range
$0.69
Now: $5.79
$9.89
Volume732.71 million shs
Average Volume19.24 million shs
Market Capitalization$133.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Second Sight Medical Products logo

Headlines

Second Sight Medical Products Inc.
January 21, 2021 |  wsj.com
Sight Sciences Announces Substantial Crossover Raise
December 1, 2020 |  prnewswire.com
Why World Sight Day Is So Important
October 7, 2020 |  msn.com
18 cat toys with thousands of positive reviews
September 8, 2020 |  usatoday.com
See More Headlines

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share

Profitability

Net Income$-33,590,000.00

Miscellaneous

Market Cap$133.85 million
Next Earnings Date3/18/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.11 out of 5 stars

Medical Sector

943rd out of 1,968 stocks

Electromedical Equipment Industry

23rd out of 61 stocks

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$5.79
+4.36 (+304.90 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

Is Second Sight Medical Products a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Second Sight Medical Products stock.
View analyst ratings for Second Sight Medical Products
or view top-rated stocks.

What stocks does MarketBeat like better than Second Sight Medical Products?

Wall Street analysts have given Second Sight Medical Products a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Second Sight Medical Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a decline in short interest in February. As of February 12th, there was short interest totaling 291,900 shares, a decline of 22.6% from the January 28th total of 376,900 shares. Based on an average daily volume of 3,180,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.7% of the shares of the company are short sold.
View Second Sight Medical Products' Short Interest
.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Second Sight Medical Products
.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) issued its quarterly earnings data on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history
.

How has Second Sight Medical Products' stock price been impacted by COVID-19 (Coronavirus)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EYES stock has increased by 64.0% and is now trading at $5.79.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EYES?

1 brokerages have issued twelve-month price targets for Second Sight Medical Products' stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.50 in the next twelve months. This suggests that the stock has a possible downside of 56.8%.
View analysts' price targets for Second Sight Medical Products
or view top-rated stocks among Wall Street analysts.

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Matthew J. Pfeffer CPA, CEO & Director (Age 63, Pay $59k)
  • Gunnar Bjorg, Founder
  • Edward Jonathon Sedo, Principal Accounting & Financial Officer
  • Mr. Edward David Randolph, VP of Operations (Age 63)
  • Mr. Stephen D. Okland Jr., Chief Strategy & Bus. Devel. Officer (Age 57)
  • Ms. Lisa M. Wilson, Founder & Pres of In-Site Communications and Investor Relations for Second Sight (Age 56)

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.11%), Jane Street Group LLC (0.09%) and Squarepoint Ops LLC (0.07%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph and Jonathan Will Mcguire.
View institutional ownership trends for Second Sight Medical Products
.

Which major investors are buying Second Sight Medical Products stock?

EYES stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jane Street Group LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Second Sight Medical Products
or or view top insider-buying stocks.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $5.79.

How much money does Second Sight Medical Products make?

Second Sight Medical Products has a market capitalization of $133.85 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Second Sight Medical Products have?

Second Sight Medical Products employs 12 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is www.secondsight.com.

Where are Second Sight Medical Products' headquarters?

Second Sight Medical Products is headquartered at 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.